MedKoo Cat#: 100940
Name: Vorinostat
CAS#: 149647-78-9
Chemical Formula: C14H20N2O3
Exact Mass: 264.14739
Molecular Weight: 264.3202
Elemental Analysis: C, 63.62; H, 7.63; N, 10.60; O, 18.16
Synonym: MK-0683, MK 0683, MK0683, SAHA, M344, CCRIS 8456, HSDB 7930, Vorinostat, suberoylanilide hydroxamic acid, Zolinza
IUPAC/Chemical Name: N1-hydroxy-N8-phenyloctanediamide
InChi Key: WAEXFXRVDQXREF-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h4-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
SMILES Code: O=C(NO)CCCCCCC(NC1=CC=CC=C1)=O
Technical Data
View CoA: current batch, Lot#BBC60705
Additional Information
References
1: Duvic M, Dimopoulos M. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. Cancer Treat Rev. 2016 Feb;43:58-66. doi: 10.1016/j.ctrv.2015.04.003. Epub 2015 Apr 9. Review. PubMed PMID: 26827693.
2: Afifi S, Michael A, Azimi M, Rodriguez M, Lendvai N, Landgren O. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat. Pharmacotherapy. 2015 Dec;35(12):1173-88. doi: 10.1002/phar.1671. Review. PubMed PMID: 26684557.
3: Iwamoto M, Friedman EJ, Sandhu P, Agrawal NG, Rubin EH, Wagner JA. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol. 2013 Sep;72(3):493-508. doi: 10.1007/s00280-013-2220-z. Epub 2013 Jul 3. Review. PubMed PMID: 23820962.
4: Lynch DR Jr, Washam JB, Newby LK. QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. Cardiol J. 2012;19(4):434-8. Review. PubMed PMID: 22825908.
5: Prebet T, Vey N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs. 2011 Feb;20(2):287-95. doi: 10.1517/13543784.2011.542750. Epub 2010 Dec 31. Review. PubMed PMID: 21192773.
6: Richon VM. Targeting histone deacetylases: development of vorinostat for the treatment of cancer. Epigenomics. 2010 Jun;2(3):457-65. doi: 10.2217/epi.10.20. Review. PubMed PMID: 22121904.
7: Kavanaugh SM, White LA, Kolesar JM. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm. 2010 May 15;67(10):793-7. doi: 10.2146/ajhp090247. Review. Erratum in: Am J Health Syst Pharm. 2010 Jul 15;67(14):1136. Kavanaugh, Shannon A [corrected to Kavanaugh, Shannon M]. PubMed PMID: 20479100.
8: Zirlik K, Nashan D, Veelken H. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors]. Pharm Unserer Zeit. 2010 May;39(3):190-6. doi: 10.1002/pauz.201000365. Review. German. PubMed PMID: 20425773.
9: Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S. Vorinostat in solid and hematologic malignancies. J Hematol Oncol. 2009 Jul 27;2:31. doi: 10.1186/1756-8722-2-31. Review. PubMed PMID: 19635146; PubMed Central PMCID: PMC2731787.
10: Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009 Aug 8;280(2):201-10. doi: 10.1016/j.canlet.2009.01.002. Epub 2009 Jan 31. Review. PubMed PMID: 19181442.
11: Heymann WR. Treatment of cutaneous T-cell lymphoma: focus on vorinostat. J Am Acad Dermatol. 2008 Oct;59(4):696-7. doi: 10.1016/j.jaad.2008.03.006. Review. PubMed PMID: 18793938.
12: Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc). 2007 Sep;43(9):585-99. Review. PubMed PMID: 17940636.
13: Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2007 Jul;16(7):1111-20. Review. PubMed PMID: 17594194.
14: Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007 Jan;25(1):84-90. Review. PubMed PMID: 17211407.
